ReviewJournal of the advanced practitioner in oncology2013
Prevention and management of tumor lysis syndrome in adults with malignancy.
Review in Journal of the advanced practitioner in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
- A Case of Spontaneous Tumor Lysis Syndrome With Acute Kidney Injury and the Timing of Chemotherapy.Cureus · 2025Article
- The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review.Cancers · 2024Review
- CXCR4-targeted theranostics in oncology.European journal of nuclear medicine and molecular imaging · 2022Review
- Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives.Molecules (Basel, Switzerland) · 2022Article
- Tumor acidity: From hallmark of cancer to target of treatment.Frontiers in oncology · 2022Review
- Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology.The American journal of case reports · 2019Article
- Tumour lysis syndrome: a rare side effect of imatinib therapy for GIST.BMJ case reports · 2018Article
- T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Toxicologic pathology · 2018Review
- Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.The oncologist · 2017Review
- Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.Journal of medical case reports · 2016Article
- Tumour lysis syndrome: A rare acute presentation of locally advanced testicular cancer - Case report and review of literature.Asian journal of urology · 2016Article
- Tumor lysis syndrome in the emergency department: challenges and solutions.Open access emergency medicine : OAEM · 2015Review
- Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia.Journal of the advanced practitioner in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS), an oncologic emergency that typically occurs after the treatment of a malignancy with chemotherapy and/or radiotherapy, is the result of extreme tumor cell lysis with the release of intracellular potassium, nucleic acids, and phosphorus into the systemic circulation. Tumor lysis syndrome occurs most often after administration of cytotoxic therapy in patients with high-grade lymphomas and acute lymphoblastic leukemia, but it can also occur spontaneously in tumor types that have a high proliferative rate and/or a large tumor burden. The metabolic disturbances of TLS include hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute renal failure. The most important treatment for TLS is prevention. The mainstays of TLS prevention include aggressive hydration, control of hyperuricemia with allopurinol and rasburicase treatment, and close monitoring of electrolyte abnormalities. It is crucial for clinicians to prevent, detect, and treat TLS early to prevent life-threatening complications such as acute renal failure, cardiac dysrhythmia, and seizures. The purpose of this article is to explain the pathophysiology of TLS, identify patients at risk for TLS, and detail strategies for prevention and management of this oncologic emergency.
Identifiers
25031988PMC4093415W2003765315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.